Anti-HCV antibody in Chinese cirrhotic patients with or without hepatocellular carcinoma: Relation to multitransfusion
Version of Record online: 10 MAR 2008
Journal of Gastroenterology and Hepatology
Volume 7, Issue 2, pages 128–131, April 1992
How to Cite
CHANG, W.-Y., WANG, L.-Y., CHUANG, W.-L., CHEN, S.-C., LU, S.-N. and YOU, S.-L. (1992), Anti-HCV antibody in Chinese cirrhotic patients with or without hepatocellular carcinoma: Relation to multitransfusion. Journal of Gastroenterology and Hepatology, 7: 128–131. doi: 10.1111/j.1440-1746.1992.tb00948.x
- Issue online: 10 MAR 2008
- Version of Record online: 10 MAR 2008
- Application for publication 21 July 1991.
- blood transfusion;
- hepatitis C virus;
- hepatocellular carcinoma;
- liver cirrhosis.
To investigate the positive rates of antibodies to hepatitis C virus (anti-HCV) in Chinese cirrhotic patients with or without hepatocellular carcinoma and to evaluate the influence of blood transfusion on the prevalence of anti-HCV in such patients, a longitudinal study in 30 cirrhotic patients (17 combined with hepatocellular carcinoma) was carried out. Five patients (16.7%) were anti-HCV positive before transfusion. The positive rate of anti-HCV in HBsAg-positive patients and HBsAg-negative patients was 9.5% (2/21) and 33.3% (3/9), respectively. The positive rates in cirrhotic patients with or without hepatocellular carcinoma were 23.5% (4/17) and 7.7% (1/13), respectively. The positive rate of anti-HCV increased significantly after multitransfusion, and the estimated infectivity of blood products was 6.1 patients per 1000 units of blood products. It was concluded that the aetiological role of hepatitis C virus on liver cirrhosis and hepatocellular carcinoma in the endemic area of hepatitis B virus is not so important as in Western countries, and transfusion might result in an overestimated pathogenic effect of hepatitis C virus in cirrhotic patients and patients with hepatocellular carcinoma.